Tetralogic Pharmaceuticals Corp (TLOG) 5.12 $TLOG
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EOPN: 8.55 (-0.01), HPJ: 5.71 (+0.16), GLUU: 5.12 (+0.14), BPFH: 13.08 (+0.22), TLOG: 5.12 (+0.36), SOFO: 8.07 (-0.16), EGLT: 10.60 (+0.58), BBSI: 39.78 (+0.84), SLAB: 49.26 (-0.27), CONN: 24.69 (-0.07), CBMG: 24.32 (-1.17), ALQA: 6.14 (+0.09), LWAY: 19.83 (+0.11)
TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
GlobeNewswire - Thu Dec 18, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T-cell lymphoma ("CTCL"
.
TLOG: 5.12 (+0.36)
Market Maker Surveillance Report. JRJC, ECSL, TLOG, WLDN, HGSH, EKSO, Losing Stocks With Lowest Price Friction For Tuesday, December 16th 2014
M2 - Wed Dec 17, 2:18AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5122 companies with "abnormal" market making, 2762 companies with positive Friction Factors and 4010 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. China Finance Online Co Ltd (NASDAQ:JRJC), ECARE SOLUTIONS INC (OTC:ECSL), TRANSFORM LOGIC CORP (NASDAQ:TLOG), Willdan Group Inc (NASDAQ:WLDN), China Hgs Real Estate Inc (NASDAQ:HGSH), (OTC:EKSO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
JRJC: 5.46 (+0.16), HGSH: 3.05 (-0.13), TLOG: 5.12 (+0.36), WLDN: 14.40 (+0.19)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:47AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), ECR: 7.29 (+0.12), BBX: 14.29 (-0.23), WG: 6.69 (+0.28), HGSH: 3.05 (-0.13), NVGN: 2.79 (+0.17), TPLM: 5.68 (+0.06), TLOG: 5.12 (+0.36), CYCC: 0.62 (-0.01), SFY: 2.91 (+0.26), BBG: 12.56 (+0.55), WRES: 1.27 (+0.01), GOL: 3.85 (+0.01), NAV: 28.52 (+0.58), WYY: 1.50 (+0.02), FNJN: 2.77 (-0.36), LINE: 12.94 (+0.40), SCX: 20.98 (+0.05), WLDN: 14.40 (+0.19)
TetraLogic Provides Update on Ovarian Cancer Study
GlobeNewswire - Tue Dec 16, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with ovarian cancer. The study is being conducted in patients who have failed up to three rounds of prior chemotherapy. In the study birinapant has been dosed twice weekly, 3 weeks out of 4, or 4 weeks out of 4, in combination with Amgen's TRAIL receptor 2 agonist antibody, conatumumab, dosed every 2 weeks. Patients are scanned for disease status after every 8 weeks (2 cycles).
AMGN: 153.48 (+0.30), TLOG: 5.12 (+0.36)
TetraLogic Pharma perking up
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 9:23AM CST
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Thu Dec 04, 6:29AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the 56 Annual American Society of Hematology meeting to be held in San Francisco from December 6-9, 2014.
TLOG: 5.12 (+0.36)
TetraLogic to Participate in Two Conferences in December
GlobeNewswire - Tue Dec 02, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that company management will participate in the following conferences in New York this month:
TLOG: 5.12 (+0.36)
Andrew L. Pecora of TetraLogic Pharmaceuticals Corporation (TLOG)-NasdaqGM bought Shares of TLOG
M2 - Thu Nov 20, 7:06AM CST
Reported by InsiderCow.com at 2014-11-19 12:36:34 ET
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B
GlobeNewswire - Mon Nov 10, 7:42AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the SMAC-mimetic, birinapant, to clear Hepatitis B Virus (HBV) in mouse models.
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals Announces Appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as New Directors
GlobeNewswire - Fri Nov 07, 10:10AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as Class I directors to fill two board slots that have been vacant since January 2014.
TLOG: 5.12 (+0.36)
TetraLogic misses by $0.08
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:25PM CST
TLOG: 5.12 (+0.36)
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Nov 05, 3:38PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2014. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
AMGN: 153.48 (+0.30), TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals to Host Investor Forum on November 10, 2014
GlobeNewswire - Mon Nov 03, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the company will host a live audio webcast in conjunction with its Investor Forum during the 2014 American Association for the Study of Liver Diseases Meeting on Monday, November 10, 2014 at 7:30 a.m. Eastern Time in Boston, MA.
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses
GlobeNewswire - Wed Aug 27, 6:39AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the preclinical studies that provide the rationale for SMAC-mimetics as a potential therapy for Hepatitis B will be presented at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses to be held in Los Angeles at UCLA from September 3-6, 2014.
TLOG: 5.12 (+0.36)
4 Stocks Under $10 Making Big Moves
at The Street - Fri Aug 08, 6:22AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
TXMD: 4.70 (-0.09), OGXI: 2.06 (-0.05), HIMX: 8.04 (+0.28), TLOG: 5.12 (+0.36)
Can the Rally in TetraLogic (TLOG) Shares Continue?
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EOPN: 8.55 (-0.01), HPJ: 5.71 (+0.16), GLUU: 5.12 (+0.14), BPFH: 13.08 (+0.22), TLOG: 5.12 (+0.36), SOFO: 8.07 (-0.16), EGLT: 10.60 (+0.58), BBSI: 39.78 (+0.84), SLAB: 49.26 (-0.27), CONN: 24.69 (-0.07), CBMG: 24.32 (-1.17), ALQA: 6.14 (+0.09), LWAY: 19.83 (+0.11)
TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma
GlobeNewswire - Thu Dec 18, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T-cell lymphoma ("CTCL"
. TLOG: 5.12 (+0.36)
Market Maker Surveillance Report. JRJC, ECSL, TLOG, WLDN, HGSH, EKSO, Losing Stocks With Lowest Price Friction For Tuesday, December 16th 2014
M2 - Wed Dec 17, 2:18AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5122 companies with "abnormal" market making, 2762 companies with positive Friction Factors and 4010 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. China Finance Online Co Ltd (NASDAQ:JRJC), ECARE SOLUTIONS INC (OTC:ECSL), TRANSFORM LOGIC CORP (NASDAQ:TLOG), Willdan Group Inc (NASDAQ:WLDN), China Hgs Real Estate Inc (NASDAQ:HGSH), (OTC:EKSO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
JRJC: 5.46 (+0.16), HGSH: 3.05 (-0.13), TLOG: 5.12 (+0.36), WLDN: 14.40 (+0.19)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:47AM CST
FRO: 2.96 (+0.07), TLM: 7.63 (-0.03), ECR: 7.29 (+0.12), BBX: 14.29 (-0.23), WG: 6.69 (+0.28), HGSH: 3.05 (-0.13), NVGN: 2.79 (+0.17), TPLM: 5.68 (+0.06), TLOG: 5.12 (+0.36), CYCC: 0.62 (-0.01), SFY: 2.91 (+0.26), BBG: 12.56 (+0.55), WRES: 1.27 (+0.01), GOL: 3.85 (+0.01), NAV: 28.52 (+0.58), WYY: 1.50 (+0.02), FNJN: 2.77 (-0.36), LINE: 12.94 (+0.40), SCX: 20.98 (+0.05), WLDN: 14.40 (+0.19)
TetraLogic Provides Update on Ovarian Cancer Study
GlobeNewswire - Tue Dec 16, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it intends to proceed with the expansion phase of its study in patients with ovarian cancer. The study is being conducted in patients who have failed up to three rounds of prior chemotherapy. In the study birinapant has been dosed twice weekly, 3 weeks out of 4, or 4 weeks out of 4, in combination with Amgen's TRAIL receptor 2 agonist antibody, conatumumab, dosed every 2 weeks. Patients are scanned for disease status after every 8 weeks (2 cycles).
AMGN: 153.48 (+0.30), TLOG: 5.12 (+0.36)
TetraLogic Pharma perking up
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 9:23AM CST
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 56th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Thu Dec 04, 6:29AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the 56 Annual American Society of Hematology meeting to be held in San Francisco from December 6-9, 2014.
TLOG: 5.12 (+0.36)
TetraLogic to Participate in Two Conferences in December
GlobeNewswire - Tue Dec 02, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that company management will participate in the following conferences in New York this month:
TLOG: 5.12 (+0.36)
Andrew L. Pecora of TetraLogic Pharmaceuticals Corporation (TLOG)-NasdaqGM bought Shares of TLOG
M2 - Thu Nov 20, 7:06AM CST
Reported by InsiderCow.com at 2014-11-19 12:36:34 ET
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B
GlobeNewswire - Mon Nov 10, 7:42AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the SMAC-mimetic, birinapant, to clear Hepatitis B Virus (HBV) in mouse models.
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals Announces Appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as New Directors
GlobeNewswire - Fri Nov 07, 10:10AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced the appointment of Mary Ann Gray, Ph.D. and Mr. Michael D. Kishbauch as Class I directors to fill two board slots that have been vacant since January 2014.
TLOG: 5.12 (+0.36)
TetraLogic misses by $0.08
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:25PM CST
TLOG: 5.12 (+0.36)
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Nov 05, 3:38PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2014. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
AMGN: 153.48 (+0.30), TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals to Host Investor Forum on November 10, 2014
GlobeNewswire - Mon Nov 03, 6:30AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that the company will host a live audio webcast in conjunction with its Investor Forum during the 2014 American Association for the Study of Liver Diseases Meeting on Monday, November 10, 2014 at 7:30 a.m. Eastern Time in Boston, MA.
TLOG: 5.12 (+0.36)
TetraLogic Pharmaceuticals to Present Data From Pre-Clinical Studies With Hepatitis B at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses
GlobeNewswire - Wed Aug 27, 6:39AM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the preclinical studies that provide the rationale for SMAC-mimetics as a potential therapy for Hepatitis B will be presented at the 2014 International Meeting on Molecular Biology of Hepatitis B Viruses to be held in Los Angeles at UCLA from September 3-6, 2014.
TLOG: 5.12 (+0.36)
4 Stocks Under $10 Making Big Moves
at The Street - Fri Aug 08, 6:22AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
TXMD: 4.70 (-0.09), OGXI: 2.06 (-0.05), HIMX: 8.04 (+0.28), TLOG: 5.12 (+0.36)
Can the Rally in TetraLogic (TLOG) Shares Continue?
